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SPRING, 1995 tTHJWIifll 26, NUMBER 1 
MALLINCKRODT INSTITUTE OF RADIOLOGY 
an Orator and the 16th Malcolm Jones Lec- 
er, MIR Director Ronald Evens spoke on "The His- 
y of Postgraduate Education in Radiology" at the 
April meeting of the American Association of Acade- 
mic Chief Residents in Radiology (A3CR2). In recogni- 
tion of 100 years of achievements in the radiation 
sciences, throughout the year radiology leaders will 
present Hartman Orations at society and educational 
meetings worldwide. The orations are named in 
honor of the late Dr. Glen Hartman, a professor of 
--   radiology at the Mayo Clinic, who spearheaded the 
Radiology Centennial. 
After the lecture Evens gathered with MIR diagnostic 
radiology residents (left to right) Farrel Van 
Wagenen, 1995-1996 cochief; Cynthia Rigsby, '94- 
'95 chief; Eric Weidman, '95-'96 chief; and Sean 
Muldowney, '94-'95 cochief. 
REFLECTIONS 
whenhe 
Wielm Conrad Roentgen would be amazed at 
he advances made in radiology since 1 895 
erTh produced that first picture of the bones in his 
wife's hand. And Doctors Warren Cole, Glover Copher, 
Evarts Graham, and Sherwood Moore of Washington 
University would be proud that their first gallbladder 
visualization was the impetus for building what has 
become one of the world's premier radiological institu- 
tions — MALLINCKRODT INSTITUTE. 
In the 64 years since the Institute began opera- 
tion, MIR scientists and clinicians have provided 
essential information for the diagnosis and 
treatment of diseases. From the development of 
roentgen kymography and positron emission 
tomography to the first medical application of 
isotopes, from identifying clinical applications 
for three-dimensional imaging to functional 
mapping of the brain — all of this groundbreak- 
ing research, and more, has come out of 
MaUinckrodt Institute of Radiology. 
At MIR, scientists and clinicians are commit- 
ted to providing the highest quality health care possi- 
ble. Through their search to DISCOVER newer and 
better methods for TREATING and HEALING dis- 
eases, the quality of life for thousands of patients has 
already improved. The following pages provide 
updates on some of that research and the changes 
affecting the Institute. 
MALLINCKRODT   INSTITUTE   OF   RADIOLOGY 
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PATIENT CARE REFLECTIONS 
The affiliation be 
tween Washington 
University School of Med- 
icine (WUMS) and 
Barnes Hospital began 
over 80 years ago. Back 
in October of 1911, a con- 
tract was drawn up with 
the provisions that the 
yet-to-be-built hospital 
would not only be staffed 
by WUMS faculty but 
would serve as the home 
base for the School's 
research and medical 
education. 
ince it first opened in 1931, the Institute has provided diagnostic radiology services 
for Barnes and, later, for Children's Hospital of St. Louis. Within the last five years, 
MIR's responsibility for diagnostic services dramatically increased. Robert Levitt, MD, 
director of radiology at Barnes West County Hospital, coordinated the EXPAN- 
SION of diagnostic services at this satellite hospital and, in the past academic year, 
produced a volume increase of more than 25 percent over previous years. Since early 
1994, Scott Mirowitz, MD, radiologist-in-chief, has guided a renovation of the diagnos- 
tic radiology facilities at Jewish Hospital. In July of 1994, William Dawson, MD, was 
appointed radiologist-in-chief of Mallinckrodt Institute's Department of Radiology at 
Barnes St. Peters Hospital. Plans are underway to include additional services and to 
enlarge the diagnostic clinical areas. 
In 1948, MIR's Radiation Oncology Center first offered high-energy radiation 
therapy to Barnes Hospital patients who were diagnosed with cancer, and the program 
was expanded in late 1983 to include Jewish Hospital. Subsequent years were marked 
by refinements in treatment techniques and a steady increase in treatment programs, 
with a tremendous growth spurt in 1994: a three-dimensional planning and quality 
assurance facility; a brachytherapy lab where physicists develop better methods for 
targeting cancers with sealed, radioactive isotopes; and, a simultaneous hyperthermia 
and external beam program at Jewish Hospital for treating small and large superficial 
tumors. 
The Institute's soon-to-be 30-year-old Division of Nuclear Medicine provides 
diagnostic nuclear medicine procedures at Barnes, Jewish, and Children's hospitals 
and consultation services at Barnes West County and Barnes St. Peters. During the 
1993-1994 academic year, MIR introduced the St. Louis region's FIRST NUCLEAR 
IMAGING with the gamma-emitting compound OctreoscanR. Collaborating with 
clinicians in the WUMS Cardiovascular Division, nuclear medicine physicians have laid 
the groundwork for an integrated cardiac stress imaging service. 
By the end of 1994, the Institute was providing professional services for five 
hospitals, and another superlative — the largest academic radiology department in 
the United States — was added to MIR's list of recognitions. While bigger is not syn- 
onymous with better, the Institute proved that additional clinical responsibilities has 
not altered our ultimate goal: providing patients and their physicians with the highest 
quality radiology services. In a recent Barnes Hospital Physician Satisfaction Survey, 
referring physicians rated their level of satisfaction with medical services, and MIR's 
diagnostic radiology and radiation oncology clinical areas each RECEIVED TOP 
RATINGS, an impressive 94 percent "very satisfied." lilllil 
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RESEARCH REFLECTIONS 
l 
Life is a gamble, butk 
perhaps no one 
more aware of that gam 
ble than the seven mil- 
lion patients in the 
United States who have 
CORONARY 
ARTERY DISEASE. 
With this disease, fatty 
deposits line the arteries 
supplying blood to the 
heart muscle. When 
those deposits harden 
and obstruct blood flow 
in the arteries, odds are 
high that the patient will 
experience pronounced 
chest pain or a heart 
attack. The odds are 
even greater that part of 
the heart muscle will die. 
Until now there was no 
diagnostic procedure 
that could accurately pre- 
dict if the myocardium 
was damaged but still 
alive, or if patients 
would benefit from 
angioplasty or surgery. 
At Mallinckrodt Institute, DR. ROBERT GROPLER of the Division of Nuclear 
Medicine has successfully used positron emission tomography (PET) to measure the 
cofW«ions among blood flow, glucose utilization, and oxygen consumption in the 
heart. Blood flow may be decreased but if oxygen and glucose are being used, then 
the heart muscle is metabolically active. And viable muscle means the patient is a 
good candidate for balloon angioplasty or bypass surgery. 
In a three-year study of more than 100 patients, an oxygen usage measurement 
with the radiolabeled compound 11C-acetate proved to be the most accurate PET mea- 
surement available to determine cardiac tissue viability. Study results are impressive. 
Eighty-five percent of the patients diagnosed with viable heart muscle have improved 
muscle function as a result of angioplasty or surgery, and they were either taken off 
medication or the dosage was reduced. If the myocardium was determined to be non- 
viable, the PET diagnosis correctly predicted (90 percent) that metabolic function 
would not return. 
Now a routinely offered clinical test at the Institute, the 45-minute, CARDIAC 
PET-with-acetate procedure is more time efficient than other diagnostic exams. Stan- 
dard imaging with 18F-fluorodeoxyglucose (measures how much sugar the heart 
metabolizes) takes nearly three hours to complete; thallium stress imaging, up to four 
hours. 
While continuing to track patient outcomes from the acetate study, Gropler will 
use PET to explore another facet of cardiac metabolism — measuring the energy effi- 
ciency of heart muscle. As principal investigator of a five-year, National Institutes of 
Health grant, Gropler, in collaboration with Washington University cardiologists, will 
study a group of 200 patients, 45 to 70 years of age, who have had a heart attack. 
"A normal heart operates at a high level of inefficiency, using only about thirty 
percent of the energy produced from contraction," says Gropler. "A damaged heart 
uses five percent or less. At Mallinckrodt Institute, we will conduct the first clinical 
investigation into the entire spectrum of why blood flow abnormalities result in certain 
myocardial functions and how we can improve energy usage." 
The research has important implications for heart patients who often need 
aggressive medical therapies. Currently, there is no measurement available to deter- 
mine if these therapies are working. According to Gropler, the ability to measure effi- 





It has been 30 year, 
since augmentation 
mammoplasty was first 
available in the United 
States. And it has been 
four years since the Food 
and Drug Administra- 
tion (FDA) banned the 
silicone gel prosthesis 
used for breast enlarge- 
ment. The ban came on 
the heels of thousands of 
lawsuits claiming that 
some women's illnesses 
were caused by the leak- 
age of silicone gel from 
their implants. 
But long before the national controversy over IMPLANTS hit the news, radiologists 
at Mallinckrodt Institute were concerned about another problem stemming from aug- 
mentation mammoplasty: 22 to 83 percent of breast tissue was blocked on mammo- 
grams because of the implant's opacity to X rays, and that opacity could cause 
early-stage breast cancer to go undetected. DRS. LOUIS GILULA, BAR- 
BARA MONSEES, and former colleague Judy Destouet were joined in their 
search for a new, radiolucent breast implant filler by Leroy Young, a Washington Uni- 
versity plastic surgeon, and JOHN EICHLING, PhD, an MIR medical physicist. 
The first breakthrough came with Eichling's demonstration that triglyceride, a 
naturally occurring fat that can be metabolized by the body, was similar in opacity to 
normal breast tissue. After subsequent testing of experimental implants filled with 
triglycerides (such as peanut and sunflower oils) provided positive results, the 
researchers were awarded a patent for a radiolucent breast implant filler. 
In August of 1994, the FDA approved a five-site, national study to pre-market 
test TRILUCENTR, an implant filled with a natural fat from soybean oil. Trilucent, 
manufactured by LipoMatrix Inc. of Palo Alto, California, in conjunction with the 
Washington University-held patent, also contains a small computer chip (called a 
transponder) that is individually coded and stores medical information about the 
patient and the implant. The information, which can be noninvasively retrieved with 
an electronic scanning device, will be entered into an international registry database 
for future follow-up. 
Women participating in the study all have augmentation implants that must be 
removed because of leakage or other complications not related to systemic medical 
problems. There are 10 patients at each of the five clinical trials — WASHINGTON 
UNIVERSITY; Johns Hopkins University; The Breast Center in Van Nuys, Califor- 
nia; the University of Florida in Gainesville; and Stanford University. 
Study participants will receive medical follow-up for at least one year following 
implantation. In addition to assessing the implant's radiolucency, researchers will 
assess capsular scarring tendencies, anatomic benefit, and changes in the patient's 
quality of life. Drs. Monsees and Young are principal investigators of the Washington 











I the summer of .1992, there wen 
approximately 500 criti- 
cally ill patients world- 
wide who owed their 
lives to a piece of metal 
and an internentional 
radiology procedure 
called TIPS — trans- 
jugular intrahepatic 
portosystemic shunting. 
f       All ol 
,    ,ems 
f the patients had developed life-threatening, esophageal or gastric bleeding prob- 
caused by chronic, progressive liver disease. When the blood flow between the 
portal vein (transports blood from the bowel and spleen to the liver) and an hepatic 
vein (receives blood from the liver) is blocked, pressure builds up in the portal vein 
and causes bleeding. If the bleeding is not controlled, the patient can die. 
There are methods other than TIPS that can treat the bleeding: endoscopic scle- 
rotherapy or surgical portosystemic shunts. But both carry risks. Injecting solutions 
into the esophagus to cause clotting carries a high incidence of recurrent bleeding and 
up to a 20 percent complication rate. And although a surgical shunt will stop the hem- 
orrhaging, the major surgery involved often results in high mortality rates, plus addi- 
tional surgery is required to remove the shunt during liver transplantation. 
At the Institute, DR. MICHAEL DARCY has led an interventional radiol- 
ogy team through 125 TIPS procedures to date. In TIPS, an expandable, metallic stent 
is guided through a sheath placed in the patient's jugular vein and into the liver. This 
shunt forms a NEW PATH FOR THE BLOOD FLOW and removes the 
pressure from the portal vein. The MIR team has perfected the method of finding the 
portal vein by modifying the angiographic techniques and using an innovative needle 
system. 
Hailed as a godsend by both patients and physicians, TIPS involves no surgery. 
The procedure does require a local anesthetic and IV sedatives but is more easily toler- 
ated by a critically ill patient than either of the alternatives. Downtime for the patient 
is usually one or two days in the hospital. There are no complications if the patient 
subsequently undergoes liver transplantation because the shunt is completely within 
the liver and is removed with the liver during the transplant. 
TIPS procedures were first done in the 1960s, using balloon dilation to open a 
tract in the liver between the portal and hepatic veins. Results were not often good 
because the pathway would quickly close down. The solution came in 1989 in the 
form of a metal, balloon-expandable stent to permanently create a blood flow path. 
As MIR's principal investigator in a Federal Drug Administration-approved, multi- 
center trial, Darcy is evaluating the efficacy of TIPS with a new self-expanding, flexible 
stent. The three-year-old trial is nearing completion, and researchers are reporting good 
results. The majority of the patients in the study have greatly benefitted from TIPS. EM 
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RESEARCH REFLECTIONS 
From the shopping J 
mall to the operat^J'- 
ing room is an unlikely 
progression by any 
stretch of the imagina- 
tion. But technology 
developed in 1983 to pro- 
duce portrait sculptures 
sold in U.S. shopping 
malls is now used suc- 
cessfully by plastic sur- 
geons in the pre- and 
postoperative evaluation 
of their patients. 
About five years ago, MICHAEL VANNIER, MD, director of the Institute's 
image processing lab, was contacted by researchers from a small St. Louis company 
called Cencit, Inc. to help create a new market for their scanner. Vannier, a pioneer in 
3-D IMAGING with expertise in congenital facial deformities, and a team of MIR 
engineers designed software and techniques to convert an existing sensing device into 
a medical facial-surface scanner. 
The resulting three-dimensional surface digitizer produces a 360-degree exami- 
nation of the head in less than one second. The free-standing, geodesic-shaped struc- 
ture houses six cameras and six strobe-light projectors, which work on a "patterned 
light" concept using ordinary white light. A zigzag pattern or grid, projected onto the 
patient's face, produces 144 images. The images are processed into 3-D data for com- 
parison with changes measured one day after surgery and again after two weeks. 
In 1991, Vannier and Leroy Young, MD, Washington University plastic and 
reconstructive surgeon, conducted a study of the new imaging system. The first 
patient was a 41-year-old female who underwent facial plastic surgery: forehead lift, 
eyelid surgery, chin implant, and facelift. Study results prove the system's ACCU- 
RACY IN MEASURING CHANGES resulting from surgery and in identifying 
and quantifying postoperative facial edema. The system's ability to distinguish 
changes due to surgery from those due to edema aids surgeons in prescribing steroidal 
therapy for patients. By modifying the data, surgeons can show their patients a com- 
puterized preview of the postoperative results and can calculate the correct size, 
shape, and volume of an implant. 
Encouraged by the success of the facial scanner, Vannier and the research team 
are exploring suitable APPLICATIONS FOR WHOLE-BODY SCANNING, 
such as orthotic and prosthetic design, breast reconstruction surgery, reduction and 
augmentation mammoplasty, scoliosis assessment, and radiation treatment planning. 
Vannier, a consultant to the Advisory Group for Aerospace Research and Development 
(NATO's oldest scientific and technical arm), says his motivation for whole-body scan- 
ning research comes from the group's quest for a multinational standard-sizing system. 
Vannier hopes to use 3-D surface imaging techniques, coupled with the expertise of 
Michael Miller, a Washington University electrical engineering professor recognized 
for his mathematical evaluations of shape and size variations, to produce a universal 
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PATIENT <M REFLECTIONS 
\piral comput 
'tomography (CT): 
technology that promise 
to be less invasive, less 
costly, and as equally 
effective as other proce- 
dures in diagnosing dis- 
eases. Across the 
country, researchers are 
conducting large-scale 
studies to determine 
whether spiral CT can 
make good on those 
promises. 
Helical or spiral CT operates on a slip-ring technology; the X-ray tube and detector 
>tate continuously in a 360-DEGREE SPIRAL MOTION around the patient. 
Sincjpe patient takes only a single breath-hold (as compared to one, five-second 
breath-hold for each of the 24 slices on conventional CT), the risk of respiratory mis- 
registration and motion artifacts on the scan is virtually eliminated. Total scanning 
time ranges from a few seconds up to one-half minute, as compared to two to three min- 
utes with conventional CT, and the imaging quality of the two technologies is comparable. 
But in an era where health care dollars are under scrutiny, the cost-effective- 
ness of spiral CT is being questioned. Proponents claim that SPIRAL CT can pro- 
duce high quality scans while using less contrast media. Opponents of this theory are 
concerned that to be competitive financially, the dose of contrast media would be 
reduced to levels that affect the quality of the scan and, ultimately, the diagnosis. 
At Mallinckrodt Institute, JAMES BRINK, MD, is principal investigator of 
a chest and abdominal study to determine the optimal dosage and delivery method of 
contrast media used with spiral CT. The Institute's 800-patient study is funded by 
the Society of Computed Body Tomography and Magnetic Resonance and by 
Nycomed Incorporated (formerly Sanofi Winthrop). The chest portion of the study is 
nearly complete, with 75 of the 300 patients remaining to be scanned using low-dose 
protocols. The completed, abdominal portion of the study involved 487 patients, ran- 
domly placed into 17 groups. Eight groups received contrast injected at a constant, 
single rate (called uniphasic); 9 groups received a higher injection rate at the begin- 
ning of the scan, a slower rate near the end (biphasic). 
The abdominal scans showed that uniphasic injection universally provided bet- 
ter results than did biphasic injection. For patients weighing less than the groups' 
mean average of 183 pounds, the uniphasic dose could be reduced by up to 50 percent 
and still produce acceptable levels of enhancement. (Based on the number of scans 
performed by a radiology facility, this dose reduction could translate into an annual 
cost savings of approximately $50,000.) In addition, dose reduction would be benefi- 
cial for patients with renal problems or for those patients who must undergo simulta- 




An interactive soft'^1 
ware package devel- 
oped in Mallinckrodt 
Institute's radiation 
physics labs is adding 
another dimension to the 
radiotherapy treatment 
of brain tumors. During 
the past two years, as 
principal investigator 
for a contract from 
Kanematsu Medical Sys- 
tems of Tokyo, 
ROBERT DRZY- 
MALA, PhD, has 
developed and fine-tuned 
a portable software pack- 
age for visualizing 
anatomy and radiation 
doses in multiple two- 
dimensional and three- 
dimensional views. The 
technology will be tested 
within the year in clini- 
cal trials at Jewish 
Hospital. 
REFLECTIONS 
The software package can run on high-end workstations that support X-windows. 
Used in tandem with imaging equipment such as computed tomography, positron 
emission tomography, magnetic resonance, and digital angiography, the software is a 
boon to radiotherapy treatment planning — both for the clinician and the patient. 
While the current system for simulating and planning STEREOTACTIC 
RADIOTHERAPY is effective, dose calculations are formatted two-dimensionally, 
one angle at a time. Coupled with a slow workstation, the treatment planning routine 
is long and laborious. The new software dovetails with the Institute's 3-D treatment 
planning system, with a special modification for the brain. This modification provides 
input for locating the center of radiation beams and for calculating radiation doses. 
During the scanning procedure, the patient's head is immobilized with a stereo- 
tactic frame that appears as dots on the scans. This DOT PATTERN indicates a 
definitive coordinate system that targets the radiation beam within one millimeter of 
the tumor. The high-speed workstation immediately shows multiple 2-D and 3-D 
views of the target area with 3-D dose distributions. Since both the planning and treat- 
ment usually can be accomplished in one day, the method is cost-effective, time effi- 
cient, and less stressful to the patient. 
The system also can aid neurosurgeons in planning brain tissue biopsies; 
implanting devices used in functional disorders, such as epilepsy, to chemically or 
physiologically manipulate brain tissue; and in treating arterial venous malformations 
and other vascular abnormalities. 
Drzymala and coinvestigators JOSEPH SIMPSON, MD, PhD, a radia- 
tion oncologist, and Keith Rich, MD, a neurosurgeon, plan to further develop the soft- 
ware to include an expanded marking or coordinate system for analyzing anatomy 
orientations. Then, the cumbersome stereotactic frame now used can be replaced 
with a simpler version. A 3-D digitizer will locate the markers established during the 
initial treatment planning and transfer the coordinates to the radiotherapy equipment, 
allowing patients to be treated in an accurate, reproducible pattern, illlll 
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RESEAR1 'M REFLECTIONS 
Eiou say that John or 
ary has a certain 
glow about them, you are 
usually referring to their 
supposed good health. 
When researchers in 
MIR's Radiation Sci- 
ences laboratories talk 
about a certain glow, 
they are probably dis- 
cussing studies using 
positron emission 
tomography (PET) and 
the glow emitted by a 
tiny, metal-bearing pep- 
tide — studies that 
promise to reclaim good 
health for cancer 
patients. 
For m any years, researchers have known that cancers grow more rapidly if they carry 
receptors for specific hormones naturally produced within the body. If scientists can 
se radiolabeled, manmade hormones (called octreotide) that will attach to the cancer 
cells, then the cell growth can be slowed or stopped. And if researchers can produce 
on-site a less expensive alternative to the commercially produced octreotides, then 
research dollars can be better applied to the fight against cancer. 
Receptors for one of these natural hormones, SOMATOSTATIN, are car- 
ried by cancerous cells in the neuroendocrine system as well as tumors of the 
prostate, breast, and lung. In the summer of 1994, as principal investigator, CAR- 
OLYN ANDERSON, PhD, received a five-year, National Institutes of Health 
grant to evaluate whether or not radiolabeled octreotide would bind to cancer cells 
containing somatostatin receptors. 
Anderson and her research team have now developed two octreotide analogs 
for radiolabeling with copper-64 and have evaluated the analogs in cells and in animal 
models. By labeling octreotide with copper-64, a positron-emitting metal, the scien- 
tists plan to set a trap: If the cells carrying somatostatin receptors bind with 
octreotide, the sites will glow when scanned with PET. Successful results would give 
oncologists a powerful tool in the diagnosis or treatment of certain cancers. 
Details of the team's octreotide syntheses were published in the Journal of 
Medicinal Chemistry. The evaluation of the radiolabeled analogs is scheduled to 
appear in the Journal of Nuclear Medicine. 
The next phase of Anderson's research is a COLLABORATIVE CLINI- 
CAL STUDY of small cell lung cancer (SCLC) tumors. In previous clinical studies 
using a gamma-emitting compound, large concentrations of somatostatin receptors 
were found in SCLC tumors. Anderson will work with FARROKH 
DEHDASHTI, MD, principal investigator of the clinical protocol, to evaluate 
somatostatin-receptor levels in SCLC tumors imaged by positron emission tomogra- 
phy and a copper-64 labeled octreotide analog. 
"Our goal is to define the potential role of PET utilizing copper-64 labeled 
octreotide as a noninvasive imaging technique in the management of SCLC," says 
Anderson. "If successful, we hope to expand the use of positron-emitting octreotide 
analogs and PET to include the management of other somatostatin-receptor positive 
tumors."  EH 
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RESEARCH 
A nine-year-old "new- 
comer" — three- 
dimensional radiation 
treatment planning and 
conformal therapy — is 
rapidly joining the 
ranks of traditional 
radiation oncology 
armamentarium. 
Buoyed by the increas- 
ing numbers of radia- 
tion oncology centers 
worldwide that are rec- 
ognizing the value of 3-D 
treatment, MIR's 
JAMES PURDY, 
PhD, one of the technol- 
ogy's pioneers, proposes 
that "radiation oncology 
will be an integrated, 
image-based medicine 
within five years." 
REFLECTIONS 
Three-dimensional treatment planning began in 1986 as a call to action by the National 
Cancer Institute: Create a program for delivering high-energy radiation safely and 
more precisely to the tumor site while sparing surrounding healthy tissue. Including 
MIR, six institutions nationwide were involved in developing the groundbreaking tech- 
nology. Purdy, chief of radiation physics, was principal investigator for two research 
contracts that led to the development of a 3-D dose planning system. The technology 
was later approved by the Food and Drug Administration and is now sold commercially. 
The St. Louis area's first 3-D TREATMENT PLANNING center opened 
at Mallinckrodt Institute in July of 1992. The center, housed in the radiation physics 
area on the sixth floor of Barnard Hospital, was equipped with an existing computed 
tomography (CT) scanner fitted with a special laser marking system and connected to 
a 3-D treatment planning computer. 
At MIR, treatment for 50 percent of patients requiring advanced planning is pre- 
scribed through the 3-D program; the most prevalent application is for lung and 
PROSTATE cancer. During the last year, workstations interfaced with 3-D planning 
systems were installed in the radiation oncology clinical areas at Barnes and Jewish 
hospitals and in the radiation physics preplanning room. At the heart of these systems 
is a new, commercially produced CT SIMULATOR with an integrated laser mark- 
ing system. The addition of multileaf collimation — devices installed on two linear 
accelerators and connected over the computer network to the planning system — 
provides conformal therapy for an average of 40 patients per month. 
A Quality Assurance Center, established in late 1994, is the clearinghouse for 
patient data submitted by nine facilities participating in a national dose escalation pro- 
tocol for localized carcinoma of the prostate. After each case is reviewed by a three- 
man assessment team (Purdy; Dr. Jeff Michalski, a radiation oncologist; and William 
Harms, a radiation physicist), results will be stored in a Washington University-devel- 
oped database that will serve as a NATIONAL RESOURCE for the analysis of 
similar dose escalation programs. 
A second national protocol for 3-D treatment planning of lung cancer is cur- 
rently under development by the Radiation Therapy Oncology Group. Approval is 
scheduled for the fall of 1995; Bahman Emami, MD, clinical director of MIR's 3-D pro- 
gram; Mary Graham, MD; and Purdy will chair the MIR/Barnes Hospital studies. liLUJ 




PATIENT CARE REFLECTIONS 
A technology-driven 
collaboration among 
industry and medical 
giants promises to make 
health care more conve- 
nient, more efficient, 
and more cost-effective. 
With that promise comes 
the realization of MIR's 
ten-year-old dream of a 
high-speed, fiber optic 
communications system 
to transmit voice, data, 
video, and high-resolu- 
tion images. 
I the mid-1980s, GILBERT JOST, MD, chief of Diagnostic Radiology, and 
\MES BLAINE, DSc, director of the Electronic Radiology Laboratory (ERL), 
orked on the "Fast Packet Project" with Jonathan Turner, PhD, and Jerome Cox, 
ScD, of the University's Department of Computer Science. With support from South- 
western Bell and several other corporate sponsors, the researchers' goal was to 
develop a high-speed ATM communications system to support the electronic storage, 
transmission, and display of medical images. That collaboration, in part, laid the 
groundwork for "PROJECT SPECTRUM," a three-year program that will pro- 
vide uniform integration of patient information from all BJC hospitals, electronic avail- 
ability of patient records for BJC-affiliated physicians, and accessibility of data and 
images from all BJC hospitals. 
BJC Health System, Washington University School of Medicine and Mallinck- 
rodt Institute, IBM, Eastman Kodak, and Southwestern Bell comprise Project Spec- 
trum's initial partnership; additional industrial members of the consortium are 
anticipated. The project's first phase began in mid-1994 with the development of pro- 
totype systems for both clinical information management and electronic image man- 
agement. High-speed telecommunications links (155 megabits per second) are in place 
at all hospitals currently served by Mallinckrodt Institute. A comprehensive clinical 
data repository soon will include patient information gleaned from thousands of med- 
ical records stored at 15 BJC hospitals and affiliates. 
A three-member executive committee steers Project Spectrum — Jost; David 
Weiss, director of BJC's management information systems; and Dr. Mark Frisse, asso- 
ciate dean for the School of Medicine's academic information management. In his 
capacity on the executive committee, Jost is responsible for coordinating the overall 
activities of the project and is specifically responsible for issues related to medical 
images. 
Blaine and Dr. Michael Kahn, director of medical informatics, are key members 
of the project. As project director for clinical information systems, Kahn is responsi- 
ble for integrating patient information from all of the BJC hospitals. As the Univer- 
sity's project director for imaging and communications initiatives, Blaine oversees the 
development of efficient, cost-effective ways to transmit diagnostic radiology images 
as well as images from other medical specialties across Spectrum's wide-reaching 
electronic network. 
As the FIRST INTEGRATED HEALTH INFORMATION SYSTEM 
nationwide to link an academic medical center with suburban and rural health facili- 
ties, Project Spectrum is capable of supporting both video and high-resolution image 
transmission to more than 5,000 affiliated physicians in a 250-mile radius. The system 




To many of us "mito- 
sis" may sound like 
a foreign language. To 
MICHAEL MACKEY, 
a PhD cancer biologist, 
this term is a familiar 
steppingstone in his 
search for an effective 
method of treating cancer 
with an age-old therapy, 
hyperthermia. 
REFLECTIONS 
The process that cells undergo to achieve normal cell division is called mitosis: After 
a cell divides, its DNA must be doubled before the cell can divide again. Premature or 
abnormal mitotic events lead to cell death. HYPERTHERMIA uses high tempera- 
tures to trick cells into dividing or attempting to divide before the completion of nor- 
mal mitosis. Based on results from numerous rodent studies and on the assumption 
that temperature levels causing rodent cell death elicited the same result in human 
cells, researchers and clinicians nationwide followed the principle that hyperthermia 
was not effective with temperatures lower than 43° Celsius. But those same high tem- 
peratures that kill cancer cells often are not tolerated well by patients and cause tech- 
nical difficulties with the heat delivery systems. 
In studies supported in 1993 by a National Institutes of Health grant, Mackey 
discovered that unlike rodent cells, human cell death continues at temperatures as low 
as 41.5°C. Further research, aided by computer and mathematical modeling, yielded 
important information that challenges accepted hypotheses about the biochemical 
basis for premature cell division. For example, conventional theory holds that prema- 
ture cell division is caused by events occurring during the regulated MITOTIC 
PROCESS. Mackey proposes there are "cascades of molecular events" and if any 
one of the components of the cascades are present in abnormally high amounts, the 
cells can be tricked into dividing before DNA replication is completed. He and Dr. 
Paul Swanson, a Washington University surgical pathologist, are examining cells by 
electron microscopy to identify new modes of cell killing. 
Mackey's original research has numerous spinoffs that all impact on the ulti- 
mate goal of clinical hyperthermia: Control the cell growth and stop the tumor from 
growing. One aspect (which Mackey calls "Ontogeny Recapitulates Phylogeny") 
focuses on a biological notion that embryonic cells from different organisms are very 
similar during early development, with each species taking a shared path on its way to 
adulthood and developing a series of steady states. Another spinoff involves the iden- 
tification of distinguishable differences between live organisms and dead organisms by 
comparing the rates of specific biochemical processes. One theory states that cells 
maintain a homeostatic or steady state even though they are constantly bombarded by 
external and internal influences, but another, the dynamic systems theory (also called 
chaos), purports that some aspects of biological systems are random or chaotic. 
Using a computer model, Mackey unified the two concepts and discovered the rates, 
although chaotic, actually mirrored each other, resulting in an overall steady state . 
Controlling cell growth is a complex problem at the molecular level, but devel- 
oping models as Mackey has allows cancer biologists to fine-tune experimentation and 
to develop hypotheses that can be tested. Lowering the temperature rate used for 
hyperthermia is showing good results in the treatment of deep-seated tumors and 
holds promise for a number of site-specific tumors such as lung, prostate, and brain. EH3 

TEACH \K\r. REFLECTIONS 
Since the first ML 
diagnostic radiology 
residents arrived in 
1931, more than 800 
of the world's brightest 
young physicians have 
received their radiology, 
nuclear medicine, and 
radiation oncology 
training at the Institute. 
The affiliation between 
Washington University 
School of Medicine and 
the BJC hospital network 
provides for a wellspring 
of cases from which the 
RESIDENTS AND 
FELLOWS, as well as 
medical students and 
technologists, can learn 
more about the detection 
and healing of diseases. 
The Institute's teaching 
programs are important 
pathways for adminis- 
tering quality patient 
care. 
bur-year diagnostic residency program offers instruction and guidance by recog- 
zed experts in the disciplines of abdominal radiology and ultrasonography, neurora- 
ology, nuclear medicine, vascular and interventional radiology, magnetic resonance 
imaging, chest radiology, computed tomography, musculoskeletal and emergency radi- 
ology, breast imaging, and pediatric radiology. A specialized five-year program to pre- 
pare the clinician scientist for an academic radiology career combines general 
diagnostic radiology training, full-time research opportunities, and concentrated 
instruction in a radiology subspecialty. As a result of the 1994 merger of the diagnostic 
residency programs at Barnes and Jewish hospitals, MIR's 68-member training pro- 
gram is the LARGEST OF ITS KIND in the United States. 
MIR's nuclear medicine/nuclear radiology residency program has a strong her- 
itage — five decades of Washington University experience in the application of 
radionuclide tracers to the biomedical sciences. Two approved learning experiences 
are available: A two-year program, open to physicians with at least one but preferably 
two or more years of postgraduate training in another specialty, fulfills the training 
requirements for American Board of Nuclear Medicine (ABNM) certification. The one- 
year option for applicants who have completed a diagnostic radiology residency meets 
the requirements for certification in diagnostic radiology with special competence in 
nuclear radiology (and usually allows the trainee also to be certified by the ABNM). 
The radiation oncology and medical physics residency programs combine 
RESEARCH and CLINICAL EXPERIENCES to strengthen and support the 
fight against cancer. Accredited in 1971, the radiation oncology program is available to 
applicants who have completed an internship and provides a four-year exposure to a 
multidisciplinary approach to the treatment of cancer. During a six-month research 
rotation, residents participate in a biology or physics project that is supervised by a 
staff member. In the two-year medical physics program, trainees gain experience in 
solving fundamental problems in dosimetry, hyperthermia, and three-dimensional 
treatment planning. 
Graduates of MIR's training programs practice in 48 states and in 25 foreign 
countries. As further testimony to Mallinckrodt Institute's reputation as a leader in 
education, more than 50 current chairs of academic radiology departments worldwide 
received their training or taught at the Institute.   IUU 
At left, Daniel Keleti, MD, 1994-1995 





rTlhe past academic year was one of accomplishments, strategic planning, and major 
JL investments in the academic and clinical futures of Mallinckrodt Institute of Radi- 
ology at Washington University. We live in and must respond to several environments 
that are all changing rapidly: Washington University, the specialty of radiology, and 
the United States health care system. At Mallinckrodt Institute, we have made major 
commitments to the traditional academic medical responsibilities of PATIENT 
CARE, EDUCATION, AND RESEARCH. 
Nationwide, many health care providers are preparing for the onset of managed 
care and managed competition by combining services to form health care networks. 
Mallinckrodt Institute is playing an important role in the BJC Health System, Mis- 
souri's first health care network, by providing the highest quality diagnostic and thera- 
peutic patient care possible. 
MIR's diagnostic and radiation oncology residency programs continue to attract 
the top radiology candidates in the nation, as is evidenced by the exceptional results of 
the yearly Matching Program. We are dedicated to preserving the integrity and quality 
of the Institute's residency and fellowship programs while broadening our research 
graduate student program. 
The Mallinckrodt Institute of Radiology at Washington University Imaging Cen- 
ter is the first step in MIR's major expansion of imaging sciences research. The 
IMAGING CENTER, which opened last November, provides a centralized loca- 
tion for studies focusing on positron emission tomography, magnetic resonance imag- 
ing, electronic radiology and computer science, neuroimaging, and 
radiopharmaceutical development. The growth in our research programs will empha- 
size collaborations with other Washington University departments. 
The past academic year has been a time of growth for the Institute. We have 
expanded not only in size (60,000 square feet of new or remodeled research space) but 
in strength (138 faculty, 90 of whom are tenured or on tenure track). Through careful 
planning and the effective use of our important resources, the Institute can become the 
highest rated academic radiology department in the United States. At MIR we are not 
just responding to an uncertain world, we are creating changes that will improve our 
scholarly activities and consequently provide BETTER SERVICE TO OUR 
PATIENTS. 
jL, Sfa-W-A 
Ronald G. Evens, MD 
Director of the Institute 
fkcm REFLECTIONS 
1 994-1 995 FULL-TIME FACULTY 
OF THE MALUNCKRODT INSTITUTE OF RADIOLOGY 
Carolyn J. Anderson, PhD 
D. Claire Anderson, MD 
Carlos F. Aquino- 
Aponte, MD 
Dennis M. Balfe, MD 
Mark M. Bahn, MD, PhD 
Gulab Bhatia, MS 
Premsri Barton, MD 
Harold F. Bennett, MD 
G. James Blaine, DSc 
Joseph A. Borrello, MD 
James A. Brink, MD 
Jeffrey J. Brown, MD 
Kun San Chao, MD 
Ming-shun Chen, PhD 
Y. Abel Cheng, MS 
Thomas E. Conturo, 
MD, PhD 
DeWitte T. Cross, MD 
Michael G. Crowley, PhD 
P. Duffy Cutler, PhD 
Michael D. Darcy, MD 
William B. Dawson, MD 
Farrokh Dehdashti, MD 
Carmen S. Dence, MS 
Jeffrey A. Dobkin, MD 
Steven Don, MD 
Robert E. Drzymala, PhD 
James R. Duncan, 
MD, PhD 
John O. Eichling, PhD 
Bahman Emami, MD 
Ronald G. Evens, MD 
Keith C. Fischer, MD 
Glenn Fletcher, PhD 
Seymour Fox, PhD 
Mokhtar H. Gado, MD 
Russell L. Gerber, MS 
David S. Gierada, MD 
Louis A. Gilula, MD 
Harvey S. Glazer, MD 
Prabhat C. Goswami, PhD 
Mary V. Graham, MD 
Perry W. Grigsby, MD 
Robert J. Gropler, MD 
Fernando R. Gutierrez, 
MD 
E. Mark Haacke, PhD 
William B. Harms, BS 
Jay P. Heiken, MD 
Thomas E. Herman, MD 
Marshall E. Hicks, MD 
Ryuji Higashikubo, PhD 
Charles F. Hildebolt, 
DDS, PhD 
Rexford L. Hill, MS 
Jacqueline C. Hodge, MD 
Fred J. Hodges, MD 
David M. Hovsepian, MD 
Paul S. Hsieh, MD     ^> 
Clayton R. Hunt, PhD 
R. Gilbert Jost, MD 
Daniel K. Kido, MD 
Eric E. Klein, MS 
Lawrence M. Kotner, MD 
Andrei Laszlo, PhD 
Benjamin C. P. Lee, MD 
Henry K. Lee, MD 
Robert G. Levitt, MD 
Debiao Li, PhD 
Hsiu-san Lin, MD 
Weili Lin, PhD 
Daniel A. Low, PhD 
Michael A. Mackey, PhD 
Robert Malyapa, MD, 
PhD 
James D. Matthews, MD 
John W. Matthews, DSc 
William H. McAlister, MD 
Timothy J. McCarthy, PhD 
Bruce L. McClennan, MD 
Kevin W. McEnery, MD 
Elizabeth Gerard 
McFarland, MD 
Robert C. McKnight, MD 
William B. Mehard, MD 
JeffM. Michalski, MD 
Mary A. Middleton, MD 
William D. Middleton, MD 
Tom R. Miller, MD, PhD 
Scott A. Mirowitz, MD 
Stephen M. Moerlein, PhD 
Barbara S. Monsees, MD 
Stephen M. Moore, MS 
Christopher J. Moran, MD 
Eduardo G. Moros, PhD 
Daniel F. Mullen, DDS 
Robert J. Myerson, MD 
Nathan C. Nelson, MS 
Gilbert H. Nussbaum, PhD 
Carlos A. Perez, MD 
Daniel D. Picus, MD 
Thomas K. Pilgram, PhD 
David Piwnica-Worms, 
MD, PhD 
Linda King Proctor, MD 
James A. Purdy, PhD 
Marcus E. Raichle, MD 
Vallabhaneni V. Rao, PhD 
William R. Reinus, MD 
Tracy L. Roberts, MD 
Douglas D. Robertson, 
MD, PhD 
Joseph L. Roti Roti, PhD 
Henry D. Royal, MD 
Stuart S. Sagel, MD 
Kondapuram S. 
Sampathkumaran, MS 
David J. Scherer, MS 
Alan E. Schlesinger, MD 
Sally W. Schwarz, MS 
Janice W. Semenkovich, 
MD 
Gary D. Shackelford, MD 
Vijay Sharma, PhD 
Peter E. Shile, MD 
Barry A. Siegel, MD 
Cary L. Siegel, MD 
Marilyn J. Siegel, MD 
Joseph R. Simpson, 
MD, PhD 
Celette S. Skinner, PhD 
Richard M. Slone, MD 
Emily L. Smith, MD 
Douglas R. Spitz, PhD 
William Straube, MS 
Marie E. Taylor, MD 
Yvonne C. Taylor, PhD 
Sharlene A. Teefey, MD 
William G. Totty, MD 
Michael W. Vannier, MD 
Thomas M. Vesely, MD 
Jerold W. Wallis, MD 
Ge Wang, PhD 
Todd H. Wasserman, MD 
Michael J. Welch, PhD 
0. Clark West, MD 
Jeffrey F. Williamson, 
PhD 
Franz J. Wippold, MD 
Darryl A. Zuckerman, MD 
Steven Winn, MD, (back to camera 
recently combined his radiology ski 
his previous veterinarian experieni 
diagnose an unusual patient — Betsy, a 
valuable block rhino in the Saint Louis 
Zoo's breeding program for endangered 
species. An ultrasound examination 
revealed an infection in Betsy's reproduc- 
tive system. 
While the Zoo's modern animal hospital 
has conventional X ray capabilities, Zoo 
veterinarian Eric Miller (right) calls upon 
MIR radiologists to assist in diagnosing 
specific problems requiring other imaging 
modalities. The long-standing collabora- 
tion between the Zoo and Mallinckrodt 
Institute plays an important role in main- 
taining the continuity of certain species for 
future generations. 
